Influence of sevoflurane on the metabolism and renal effects of compound A in rats.

Kharasch E.D., Schroeder J.L., Sheffels P., Liggitt H.D. (2005) Influence of sevoflurane on the metabolism and renal effects of compound A in rats. Anesthesiology, 103(6):1183-8.

 PubMed


Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.

Chaobal H.N., Kharasch E.D. (2005) Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clinical pharmacology and therapeutics, 78(5):529-39.

 PubMed


Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.

Kharasch E.D., Walker A., Hoffer C., Sheffels P. (2005) Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity. Journal of clinical pharmacology, 45(10):1187-97.

 PubMed


CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition.

Kharasch E.D., Thummel K.E., Watkins P.B. (2005) CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Molecular interventions, 5(3):151-3.

 PubMed


Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.

Klees T.M., Sheffels P., Thummel K.E., Kharasch E.D. (2005) Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology, 102(3):550-6.

 PubMed


Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.

Klees T.M., Sheffels P., Dale O., Kharasch E.D. (2005) Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug metabolism and disposition: the biological fate of chemicals, 33(3):303-11.

 PubMed


Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans.

Dembo G., Park S.B., Kharasch E.D. (2005) Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology, 102(2):409-15.

 PubMed


Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.

Kharasch E.D., Whittington D., Hoffer C., Krudys K., Craig K., Vicini P., Sheffels P., Lalovic B. (2005) Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies. Clinical pharmacokinetics, 44(7):731-51.

 PubMed


Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.

Kharasch E.D., Walker A., Hoffer C., Sheffels P. (2005) Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination. Journal of clinical pharmacology, 45(1):79-88.

 PubMed